8-K: Klotho Neurosciences Faces Nasdaq Delisting Due to Non-Compliance with MVPHS and MVLS Requirements

Klotho Neurosciences, Inc. received a delisting notice from Nasdaq due to non-compliance with minimum Market Value of Publicly Held Shares (MVPHS) and minimum Market Value of Listed Securities (MVLS) requirements, and has requested a hearing to appeal the decision.

Summary

• Klotho Neurosciences, Inc. received delinquency notification letters from Nasdaq on August 16, 2024, due to non-compliance with Nasdaq Listing Rules 5450(b)(2)(C) and 5450(b)(2)(A).
• The company failed to meet the minimum Market Value of Publicly Held Shares (MVPHS) and minimum Market Value of Listed Securities (MVLS) requirements.
• Nasdaq provided the company with 180 calendar days, until February 12, 2025, to regain compliance.
• On February 14, 2025, Klotho Neurosciences received a delisting notice from Nasdaq.
• The company requested a hearing to appeal the delisting determination on February 21, 2025, and paid the applicable fee.
• The hearing request stays the suspension of the company's securities and the filing of Form 25-NSE pending the Panel's decision.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice, indicating financial and compliance challenges. However, the appeal process offers a glimmer of hope.

Positives

• Klotho Neurosciences has exercised its right to appeal the delisting determination.
• The appeal process stays the suspension of the company's securities and the filing of Form 25-NSE pending the Panel's decision, providing the company with an opportunity to present its case.

Negatives

• Klotho Neurosciences has received a delisting notice from Nasdaq.
• The company failed to regain compliance with the minimum Market Value of Publicly Held Shares (MVPHS) and minimum Market Value of Listed Securities (MVLS) requirements within the given timeframe.

Risks

• There is a risk that the Nasdaq panel will not rule in favor of Klotho Neurosciences, which would result in the delisting of its securities.
• Delisting from Nasdaq could negatively impact the company's stock price and its ability to raise capital.

Future Outlook

The future of Klotho Neurosciences' listing on Nasdaq depends on the outcome of the appeal hearing.

Management Comments

• Joseph Sinkule, Chief Executive Officer, signed the report on behalf of Klotho Neurosciences, Inc.

Industry Context

Delisting notices are not uncommon for companies that fail to meet Nasdaq's listing requirements, particularly smaller companies or those facing financial difficulties. The outcome of the appeal will determine whether Klotho Neurosciences can remain listed on the exchange.

Comparison to Industry Standards

• Many biotech companies face challenges in maintaining listing compliance, especially during periods of clinical trial setbacks or funding difficulties.
• Companies like Cassava Sciences (SAVA) have faced scrutiny regarding their clinical data, impacting their market capitalization and potentially leading to listing concerns.
• Other companies in the biotech sector, such as Amylyx Pharmaceuticals (AMLX), have experienced significant stock price volatility based on regulatory decisions and clinical trial results, which can affect their compliance with listing requirements.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment if the company is delisted.
• Employees may face uncertainty regarding their job security.
• The company's ability to raise capital and fund its operations could be negatively impacted.

Next Steps

• Klotho Neurosciences will participate in a hearing with the Nasdaq Listing Qualifications Department to appeal the delisting determination.
• The Nasdaq panel will make a decision regarding the company's listing status.

Key Dates